Compare UXIN & AGMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UXIN | AGMB |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | China | Belgium |
| Employees | N/A | 62 |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 558.7M | 562.4M |
| IPO Year | 2018 | N/A |
| Metric | UXIN | AGMB |
|---|---|---|
| Price | $2.14 | $11.34 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $32.00 |
| AVG Volume (30 Days) | ★ 110.7K | 64.9K |
| Earning Date | 04-10-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $245.77 | N/A |
| Revenue Next Year | $44.72 | $17.86 |
| P/E Ratio | $4.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.14 | $9.00 |
| 52 Week High | $5.32 | $17.45 |
| Indicator | UXIN | AGMB |
|---|---|---|
| Relative Strength Index (RSI) | 26.10 | 51.68 |
| Support Level | N/A | $9.62 |
| Resistance Level | $3.18 | $12.29 |
| Average True Range (ATR) | 0.17 | 0.93 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 10.62 | 36.97 |
Uxin Ltd is an investment holding company. Along with its subsidiaries, the firm operates a car retailer, pioneering industry transformation with production, new retail experiences, and digital empowerment in China. With its inventory-owning model, it provides customers a comprehensive transaction solution that encompasses the entire value chain, ranging from used-car acquisition, inspection, and reconditioning, warehousing, as well as pre-sales and after-sales services. The group offers high-quality and value-for-money used cars as well as superior full suites of services to customers through a reliable, one-stop, and hassle-free transaction experience. It derives revenues from retail vehicle sales, wholesale vehicle sales, and other businesses. The Group generates its revenues in China.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.